Literaturverzeichnis
Alle Studien aus dem
LITERATURVERZEICHNIS
können Sie in unserem Online-Service kostenlos abrufen. Tragen Sie bitte einfach Name und
Autor(en) der gewünschten Studie ins Bestellformular ein.
1) Ariyananda PL, Agnew JE, Clarke SW. Aerosol delivery systems for bronchial asthma. Postgrad Med J, 1996, 72, 151 - 156
2) Aubier M, Wettengel R, Gans SJM. Efficacy of HFA-beclomethasone dipropionate extrafine aerosol (800 µg/day) versus HFA-fluticasone propionate (1000 µg/day) in patients with Asthma. ACAAI Annual Meeting; Abstract Book; Nov 12-17, 1999
3) Ayers JG, Cline A.Safety of HFA - 134a propellant exposure over 6 - 12 weeks in asthmatics. Eur Respir J, Sept 1997, Vol 10, SuppI 25, 237s (Abs P1525)
4) Barnes PJ. Current therapies for Asthma. Chest, 1997, Vol 111, 17 - 26
5) Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med, 1998,1570), SI-S53
6) Bergmann KC, Cegla UH, Ederle K, Fischer J, Köhler D, Mitfessel H, Möller M, Petro W, Schultze - Werninghaus G, Sturm J, Thal W, Wackerbeck G. Zur Bewertung eines neuen, inhalativen FCKW-freien Glukokortikoids. Stellungnahme eines Expertengremiums - Januar 1998. Atemw.-Lungenkrkh., Jahrgang 24, Nr. 5/1998, 240-241
7) Borgström L, Bondesson E, Morén F, Trofast E, Newman SP. Lung deposition of budesonide inhaled via Turbohaler®: a comparison with terbutaline sulphate in normal subjects. Eur Respir J, 1994, Vol 7, 69-73
8) Brogden RN, Heel RC, Speight TM, Avery GS. Beclomethasone dipropionate. A reappraisal of its pharmacodynamic properties and therapeutic efficacy after a decade of use in asthma and rhinitis. Drugs, 1984, 28, 99 - 126.
9) Busse W, Colice G, Hannon S. CFC-BDP requires 2,6 times the dose to achieve equivalent improvement in FEV1 as HFA-BDP. Am J Respir Crit Care Med, March, 1998, Vol 157(3), A405
10) Busse W, Colice G, Schmitt K. Higher doses of CFC-BDP (estimated 2,6 times) needed to produce equivalent improvement in FEV1 as lower doses of HFA-BDP. Eur Respir J, Dec 1998, Vol 12, Suppl 29, 81s, P631; Posterpräsentation anlässlich des WAM im Dez. 1998, Barcelona Spanien
11) Busse W, Schmitt K, Colice G. Improved asthma symptom control with 100 mcg/day HFA-BDP but not with 100 mcg/day CFC-BDP. Am J Respir Crit Care Med, March 1998, Vol 157(3), A405
12) Busse W, Brazinsky S, Jacobson K, Strickner W, Schmitt K, Vanden Burgt J, Donnell D, Hannon S, Colice GL. Efficacy response of inhaled beclomethasone dipropionate in asthma is proportional to dose and is improved by formulation with a new propellant. J Allergy Clin Immunol December 1999, 1215 - 1222
13) Cocguic Y, Zureik M. Evaluation de la manipulation en pratique courante d'un aérosol-doseur déclenché par l'inspiration (système Autohaler®). Rev Pneumol Clin, 1997; 53 ; 13 - 19
14) Cohen R, Fireman P, Windom H. Long term safety of beclomethasone dipropioate extrafine aerosol (HFA-BDP). Abstract San Diego 4/99
15) Cegla UH. Optimierung der Inhalationstherapie - Autohaler®& Co Topmedizin, 1996, 10, Vol 3, 2 - 9
16) Conway JH, Holgate ST. Targeting therapy to inflamed airways in asthma. J Aerosol Med, 1994, 7, 161-165
17) Davies R, Stampone P, O'Connor BJ. Hydrofluoralkane - 134a beclomethasone dipropionate extrafine aerosol provides equivalent asthma control to chlorfluorcarbon beclomethasone dipropionate at approximately half the total dally dose. Respir Med, June 1998, Vol 92, Suppl A, 23 - 31
18) Deutsche Atemwegsliga. Empfehlung zur Asthmatherapie bei Kindern und Erwachsenen. Pneumologie, 1998, Vol 52, 591 - 601
19) Donnell D, Harrison LI, Ward S, Klinger NM, Eckholt BP, Cooper KM, Porietis I, McEwan J. Acute safety of the CFC - free propellant HFA - 134a from a pressurized metered dose inhaler. Eur J Clin Pharm, 19951, Vol 48, 473-477
20) Everard ML, Devadason SG, SouU PN. Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler. Respir Med, 1997, Vol 91, 624 -628
21) Fairfax AJ, Spelman R. 400 mcg HFA-beclomethasone dipropionate extrafine aerosol (QVAR®) demonstrates equivalent improvement in asthma control to 400 mcg CFC-fluticasone propionate (FlixotideTM). Am J Respir Crit Care Med, March1999, Vol 159(3), Part 2 of 2, A 630, Posterpräsentation anläßlich des ATS im April 1999 San Diego USA
22) Fischer J. Angewandte Inhalationstechnologie - Möglichkeiten der Therapieoptimierung. In: Fortschritte in der Inhalationstechnologie und ihre therapeutische Relevanz, Edition Medizin & Wissenschaft, 1999, Hrsg.: Institut für Medizin & Wissenschaft, Verlag Medizin & Wissenschaft, Senden, 13 - 21
23) Gabrio BJ, Valesquez DJ, MeNally RA. Spray force and temperature of CFC and HFA - 134a propellant aersosol MDIs. Thorax, Dez 1997, Vol 52, Suppl 6, A81 (Abs P203)
24) Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, NHLB/WHO Workshop Report, National Institutes of Health. National Heart, Lung, and Blood Institute, Jan 1995, Reprinted 1996, Publication Number 95 - 3659
25) Gross G. Thompson P J, ChervinskY P, Vanden Burgt J, and the Study Group. Hydrofluoralkane - 134a beclomethasone dipropionate, 400 µg is as effective as chlorfluorocarbon beclomethasone dipropionate, 800 µg, for the treatment of moderate asthma. Chest, Feb 1999,115, Vol 2, 343 - 351
26) Haidl P. Neue Wege in der Aerosoltherapie. Entwicklung FCKW-freier Treibgase-Pulverinhalationssysteme. Fortschritte der Medizin, 1999, Jg. 117, Nr 8, 34 - 39
27) Hamid QA. Inflammation of small airways in asthma. J Allergy, Clin Immunol, 1997, Vol 100(1),44-51
28) Hamid QA. Peripheral inflammation is more important than central inflammation. Respir Med, Nov 1997, Vol 91, Suppl A, 11 - 12
29) Harrison LI, Cline A, Wells TM, Jacobson JP, Cooper KM, Chang SF, Nelson JR, Ekholm BP, Morganroth J. Systemic concentrations of Salbutamol and HFA-134a after inhalation of Salbutamol-Sulfate in a chlorofluorocarbon-free system. Therapeutic Drug Monitoring, 1996, Vol 18, 240 - 244
30) Harrison LI, Colice GL, Donnell D, Inmaculada S, Dockhorn R. Adrenal effects and pharmacokinetics of CFC-free beclomethasone dipropionate: a 14-day dose-response study. J Pharm Pharmacol, 1999, Vol 51, 263 - 269
31) Harrison LI, Donnell D, Simmons JL, Ekholm BP, Cooper KM, Wyld PJ. Twenty-eight-day double-blind safety study of an HFA 134a inhalation aerosol system in healthy subjects. J Pharm Pharmacol, Jun 1996, Vol 48, Suppl 6,596 - 600
32) Harrison LI, Purrington A, Leach C, Machacek J, Vanden Burgt J, Vogel J, Chercham D. Ein FCKW-freies, extrafeines Steroid-Aerosol erreicht mit kleineren Teilchengrößen eine verbesserte Lungendeposition, Wirkstoffaufnahme, Wirksamkeit und Verträglichkeit. In: Aerosole in der Inhalationstherapie 11, 1998, Dustri-Verlag, München-Deisenhofen, 90 - 94
33) Hindle M, Byron PR. Dose emissions from marketed dry powder inhalers. International Journal of pharmaceutics 1995; 116; 169 - 177.
34) June DS, Schultz DW. Improved performance characteristics of CFC-free aerosol MDls. J Aerosol Med, April 1995, Vol 1(8), 91, (Abs P89)
35) Keiloway JS, Wyatt RA, Amies MH, Ekholm BP, Hahn MA. A pharmacoeconomic evaluation of Pirbuterol delivered via a new breath-actuated metered dose inhaler or a conventional MDL. Eur Respir J, 1995, Vol 8, Suppl 19, 483s (Abs P2372)
36) Kiebart M, Cloes R, Hader S. Wirtschaftlichkeit von Salbulair-Autohaler versus Salbutamol-MDI. In: Aerosole in der Inhalationstherapie 11, 1998, Dustri-Verlag, München-Deisenhofen, 95-98
37) Köhler D. Wirksamkeit und Akzeptanz von Pulverinhalatoren. Dtsch Med Wschr, 1995,120,1401 - 1404
38) Köhler D, Fleischer W. Was ist gesichert in der Inhalationstherapie? Arcis-Verlag, 1988, München, ISBN 3-89075-011-7
39) Kraft M, Djukanovic R, Wilson S, Holgate ST, Martin RJ. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med, 1996, Vol 154,1505 - 1510
40) Laitinen LA, Dahl R, Reichel W, Ringdal N, Zetterstrom O. HFA-beclometasone dipropionate extrafine aerosol (400µg) equivalent to budesonide (800 µg) in moderate asthma. Eur Respir J, 1999, Vol 14, Suppl 30, 466S (Abs P3101)
41) Leach CL. Enhanced drug delivery through reformulating MDls with HFA propellants - drug deposition and its effect on preclinical and clinical programs. Respir Drug Delivery, 1996, Vol 5, 133 - 144
42) Leach CL. Improved delivery of inhaled steroids to the large and small airwavs. Respir Med, June 1998, Vol 92, Suppl A, 3 - 8
43) Leach CL, Davidson P, Boudreau RJ. Comparison of a breath-actuated MDI to coordinated and discoordinated technique with press & breathe HFA-beclomethasone dipropionate NIDIs. Eur Respir J, Sept 1997, Vol 10, Suppl 25,126s (Abs P0890); Posterpräsentation anläßlich des ERS Sept 1997, Berlin
44) Leach DL, Davidson PJ, Boudreau RJ. Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone. Eur Respir J, 1998, Vol 12, 1346 - 1353
45) Leach CL, Davidson P, Boudreau R. Increased lung and decrease mouth deposition from a CFC-free HFA-beclomethasone MDI compared to CFC-beclomethasone MDI. Eur Respir J, Dec 1998, Vol 12, Suppl 29, 7s, P053; Posterpräsentation anlässlich des WAM im Dezember 1998, Barcelona, Spanien
46) Leach CL, Davidson PJ, Bredow TS, Boudreau RJ. Breath-activated MDI provides optimal lung deposition of HFA-Beclomethasone compared with press & breathe metered dose inhaler in asthmatic patients. Am J Respir Crit Care Med, April 1998, Vol 157(3), A637
47) Leach CL, Davidson P, Heilman J, Boudreau RJ. Improved lung deposition and decreased oropharyngeal deposition with a new CFC-free beclomethasone metered dose inhaler. Am J Respir Crit Care Med, April 1997, Vol 155(4), Part 2 of 2, A667
48) Leach CL, Davidson P, Heilman J, Boudreau RJ, Chercham D. Erhöhte Lungendeposition bei verminderter Deposition in Mund und Rachen mit einem neuen FCKW-freien Beclometason-Dosieraerosol. In:Aerosole in der Inhalationstherapie 11, 1998, Dustri-Verlag, München-Deisenhofien, 99 - 103
49) Leach CL, Davidson P, Vanden Burgt J, Boudreau RJ. Breath-actuated MDI delivers 60% airwav deposition with a new CFC-free beclomethasone formulation. Eur Respir J, Sept 1996, Vol 9., Suppl 23, 255s (Abs P1621)
50) Magnussen H. In moderate stable asthma 400 µg/d Beclomethasone Dipropionate (BDP) delivered by metered dose inhaler (MDI) with HFA 134a propellant is as effective as 1000 µg/d BDP inhaled from MDI containing CFC. Eur Respir J, Sept 1998, Vol 12, Suppl 28, 61s (P0470)
51) Marshik PL, Larsen JS, Leach CL, Halverson PC, Ekholm BP, Amies MH, Kaiser HB, Weisberg SC, Sellers JA. A novel breath actuated device (Autohaler, TM) consistently actuates during the earlv phase of inspiration. J Aerosol Med, 1995, Vol 8(2), 187 - 195
52) Martin RJ. Small airway and alveolar tissue changes in nocturnal asthma. J Respir Crit Care Med, May 1998, Vol 157(5), Part 2 of 2, S188 - S190
53) Matthys H, Nowak D, Hader S, Kunkel G. Efficacy of chlorofluorcarbon-free beclomethasone dipropionate 400 µg day delivered as an extrafine aersosol in adults with moderate asthma. Respir Med, June 1998, Vol 92, Suppl A, 17 - 22
54) Morken MA, Ruble SA, Ross DL. Delivery characteristics of three steroid aerosol delivery Systems. Am J Respir Crit Care Med, April 1997, Vol. 155(4), Part 2 of 21, A669
55) National Institutes of Health-, National Heart, Lung, and Blood Institute. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. NHI Publication, April 1997, No. 97 - 4051
56) Newman SP, Weisz AWB, Talaee N, Clarke S. Improvement of drug delivery with a breath-actuated pressurised aerosol for patients with poor inhaler technique. Thorax, 1991, Vol 46, 712-716
57) Pavia D, Thomson ML, Shannon H. Aerosol inhalation and depth of deposition in the human lung. Arch Environ Health, 1977, Vol 32, 131 - 137
58) Poutler LW. Central inflammation is more important than peripheral inflammation. Respir Med, Nov. 1997, Vol 91, Suppl A, 9 - 10
59) Purewal TS, Dahya H, Gabrio BJ. Metered dose inhaler technology improvernents introduced by a non-CFC beclomethasone dipropionate inhaler. Eur Respir J, Dec 1998, Vol 1, Suppl 29, 7s, (Abs PO55)
60) Rinderknecht J, Shapiro L, Kranthammer M, Taplin G, Wassermann K, Uszler JM, Efros RM. Accelerated clearance of small soluts from the lungs in intestinal lung disease. Am Rev Respir Dis, 1980, Vol 121,105 - 117
61) Ross DL, Morken MA, Saydah SH, Ruble SA. The effect of flow rate on particle size and fine particle dose with CFC-free breath-actuated steroid inhalers. Eur Respir J, Sept 1997, Vol 10, Suppl 25, 37s (Abs PO344)
62) Ross DL, Schultz RK. Effect of inhalation flow rate on the dosing characteristics of dry powder inhaler (DPI) and metered dose inhaler (MDI) products. J Aerosol Med Deposition, Clearance and Effects in the Lung, 1996, Vol 9(2), 215 - 226
63) Schatz M. Asthma treatment during pregnancy: What can be safely taken? Drug Safety 1997, Vol 16 (5), 342-350
64) Schultze-Werninghaus G. Ventolair®-Autohaler®: Wirksamkeit und Sicherheit. In: Fortschritte in der Inhalationstechnologie lind ihre therapeutische Relevanz, Edition Medizin & Wissenschaft, 1999, Hrsg.: Institut für Medizin & Wissenschaft, Verlag Medizin & Wissenschaft, Senden, 22 - 28
65) Schultze-Werninghaus G. Fortschritte der Asthmatherapie durch verbesserte Inhalationstechnologie - das erste Beclomethason-Dipropionat-Lösungsaerosol. Allergo J, 2000, Vol 9; 3; 149 - 152
66) Schultze-Werninghaus G. Kongressbericht: Modernes Asthmamanagement - neue Aspekte durch FCKW-freie Dosieraerosole. Pneumologie 1997; 51; 871 - 875
67) Scott WG, Scott HM, Frost GD. Pharmaeconomic evaluation of asthma treatment costs. J Medical Economics, 1997, Vol 11, 87 - 101
68) Scott WG, Scott HM, Penrose A, Frost GD, Hall J, MacKenzie DI. Economic evaluation of inhalers used in the treatment of asthma. J Medical Economics, 1998, Vol 1, 1 - 18
69) Shaw RJ. Inhaled corticosteroids for adult asthma: impact of formulation and delivery device on relative pharmacokinetics, efficacy and safety. Respir Med, 1999, Vol 93,149 - 160
70) Shaw RJ, Donnell D. Evaluation of the side-effect profile of HFA-BDP extrafine aerosol compared with conventional CFC-BDP. Posterpräsentation anlässlich des WAM im Dezember 1998 Barcelona, Spanien
71) Shaw RJ, Spiers RJ, Donnell D. Low incidence of side effects of HFA-BDP extrafine aerosol (QVAR®. Eur Respir J, Dec 1998, Vol 12, Suppl 29, 80s, (Abs P627)
72) Thompson PJ, Davies RJ, Young WF, Grossman AB, Donnell D. Safety of HFA-134a beclomethasone dipropionate extrafine aerosol. Respir Med, 1998, Vol 92, Suppl A, 33 - 39
73) Vignola AM, Bousquet J, Chanez P et al. Assessment of airway inflammation in asthma. Am J Respir Crit Care Med, 1998,157, S184 - S187
74) Voshaar T. FCKW-freie Dosieraerosole. In: Aerosole in der Inhalationstherapie 11, 1998, Dustri-Verlag, München-Deisenhofen, 75 - 86
75) Waitzinger J, Wenske H, Fackelmayer A, Schmidt P, Pabst G, Michael-Hepp J, Stechert R. Untersuchungen zur Lungendeposition von Flunisolid. Atemw.-Lungenkrkh, 1997, Vol23(5),271 - 278
76) Wenske H. Lungendeposition von radioaktiv markierten Aerosolen. Pneumol. Notizen, 1996, Vol 1(1), 16 - 20
77) Woolcock AJ. Effects of drugs on small airways. Am J Respir Crit Care Med, 1998, Vol. 157(5), part 2, S203 - S207
78) Worth H. Inhalative Steroide in der Asthma-Therapie - neueste Vergleichsstudien von Ventolair® mit Fluticason und Budesonid. In: Fortschritte in der Inhalationstechnologie und ihre therapeutische Relevanz, Edition Medizin & Wissenschaft, 1999, Hrsg.: Institut für Medizin & Wissenschaft, Verlag Medizin & Wissenschaft, Senden, 29 - 31
79) Worth H, Muir JF, Pieters WR on behalf of the multi-centre group Fürth. Efficacy of HFA-beclomethasone dipropionate extrafine aerosol from an breath-actuated device versus budesonide from a turbo inhaler at twice the dose. Europ Respir J. 1999, 14, Suppl 30; 197
80) Zellner, R. Ozonschichtabbau und Klimaänderungen. In: Pneumologische Umweltmedizin - Atemwegsorgane und Umwelt, Hrsg Schultz K, Petro W Springer Verlag 1998, ISBN 3-540-63706-0, 569-576